Charles River Laboratories International, Inc.

Health Care
Biotechnology: Commercial Physical & Biological Resarch
www.criver.com

Earnings Score
Moat Score
Safety Score

Market Cap $8.34B
PE 810
Debt $2.24B
Cash $205.57M
EV $10.37B
FCF $501.61M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$10.30M
EBIT	$227.35M
ROE	0%
ROA	3%
FCF	$501.61M
Equity	$3.47B
Growth Stability	2%
PE	809.65
PEG	-74.5
PB	2.4
P/FCF	16.62
P/S	2.06
Price/Cash	0.02
Debt/Equity	0.65
Debt/FCF	4.47
Net Margins	0%
Op. Margins	6%
Earnings CAGR	11%
Sales Growth YoY	-1%
Sales Growth QoQ	-1%
Sales CAGR	14%
FCF CAGR	7%
Equity CAGR	21%
Earnings Stability	0.14
Earnings Growth YoY	-215%
Earnings Growth QoQ	-414%

Earnings CAGR 5Y	-11%
Sales CAGR 5Y	10%
FCF CAGR 5Y	-0%
Equity CAGR 5Y	18%
Earnings CAGR 3Y	4%
Sales CAGR 3Y	4%
FCF CAGR 3Y	21%
Equity CAGR 3Y	15%
Market Cap	$8.34B
Revenue	$4.05B
Assets	$7.53B
Total Debt	$2.24B
Cash	$205.57M
Shares Outstanding	51.14M
EV	10.37B
Earnings Score	9%
Moat Score	28%
Safety Score	56%
Final Score	31%
Working Capital	408.97M
Current Ratio	1.41
Shares Growth 3y	0%
Equity Growth QoQ	-8%
Equity Growth YoY	-4%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

SEC Filings

Direct access to Charles River Laboratories International, Inc. (CRL) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 28
- 10-Q Sep 28
- 10-Q Jun 29
- 10-Q Mar 30
2023
- 10-K Dec 30
- 10-Q Sep 30
- 10-Q Jul 01
- 10-Q Apr 01
2022
- 10-K Dec 31
- 10-Q Sep 24
- 10-Q Jun 25
- 10-Q Mar 26

Sector Comparison

How does Charles River Laboratories International, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Charles River Laboratories International, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 11%

Stability 14%

loading chart...

Charles River Laboratories International, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Charles River Laboratories International, Inc..

Years

Calculation mode

= $8.3B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$502M	$539M	$578M	$621M	$667M	$716M	$769M	$826M	$886M	$952M	$1B	$10B
DCF		$490M	$478M	$467M	$455M	$445M	$434M	$424M	$414M	$404M	$394M	$3.9B
Value	$8.3B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	11%	9%	7%	10%	10%	12%	11%	12%	11%	0%	0%
ROA	-	9%	10%	9%	7%	8%	8%	9%	8%	3%	3%
ROE	-	18%	12%	17%	15%	17%	15%	16%	13%	0%	0%

Bad Net Margins (0.25%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	4.74	4.86	5.54	5.62	5.3	5.01	9.19	7.26	4.47	4.47
Debt over Equity	1.17	1.48	1.09	1.26	1.17	0.95	1.05	0.91	0.74	0.65	0.65
Growth Stability	-	-	-	100%	100%	100%	100%	100%	100%	2%	2%

Bad Debt/FCF ratio (4.47)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Good Debt/Equity ratio (0.65)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (2%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	23%	10%	22%	16%	12%	21%	12%	4%	-2%	10%
Earnings YoY growth	-	4%	-20%	84%	11%	45%	7%	24%	-2%	-98%	-11%
Equity YoY growth	-	14%	25%	26%	24%	29%	20%	17%	21%	-4%	18%
FCF YoY growth	-	16%	-10%	28%	13%	12%	40%	-45%	24%	37%	-0%